Raised copeptin has also been associated with CVD mortality in patients with type 2 diabetes complicated by end-stage renal disease or acute MI, as well as in individuals with diabetes who are treated in primary care and those in the general population [14–18]. This evidence concerns the gene AVP and chronic kidney disease.